Brokerage firm Jefferies Maintains its rating on Lantheus Holdings Inc(NASDAQ:LNTH). In a research note issued to the investors, the brokerage major Raises the price-target to $12.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Aug 29, 2016.
Lantheus Holdings Inc (LNTH) shares turned negative on Thursdays trading session with the shares closing down -0.02 points or -0.21% at a volume of 4,84,476. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $9.7402. The peak price level was also seen at $9.7402 while the days lowest was $9.36. Finally the shares closed at $9.5. The 52-week high of the shares is $10.1 while the 52-week low is $1.76. According to the latest information available, the market cap of the company is $289 M.
Lantheus Holdings Inc(LNTH) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $77.97M. Analysts had an estimated revenue of $72.66M. Earnings per share were $0.24. Analysts had estimated an EPS of $0.06.
Lantheus Holdings Inc. is engaged in developing manufacturing selling and distributing diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company’s medical imaging agents are used to diagnose coronary artery disease congestive heart failure stroke peripheral vascular disease and other diseases. The Company’s products include contrast agents and medical radiopharmaceuticals including technetium generators. The Company’s products include DEFINITY TechneLite Xenon Xe 133 Gas Cardiolite Neurolite Thallium Tl 201 Gallium Ga 67 Gludef Quadramet and Ablavar. The Company is also engaged in developing agents such as Flurpiridaz F 18 which is a myocardial perfusion imaging agent; 18F LMI 1195 which is a cardiac neuronal imaging agent and LMI 1174 which is a vascular remodeling imaging agent.